Olena Zimba, Chokan Baimukhamedov, Burhan Fatih Kocyigit
{"title":"迟发性类风湿关节炎:临床特征、诊断挑战和治疗方法。","authors":"Olena Zimba, Chokan Baimukhamedov, Burhan Fatih Kocyigit","doi":"10.1007/s00296-025-05908-1","DOIUrl":null,"url":null,"abstract":"<p><p>Late-Onset Rheumatoid Arthritis (LORA) is receiving increased clinical attention due to global aging trends. LORA presents distinct diagnostic, clinical, and therapeutic challenges. It often presents with a balanced gender distribution, acute onset, preferential involvement of larger joints, and decreased seropositivity. The diagnostic process is complex due to atypical presentations, comorbidities, and limitations of classification criteria, which insufficiently address the heterogeneity of LORA phenotypes. Patients with LORA often experience age-related geriatric syndromes, including frailty, cognitive decline, and malnutrition, in addition to comorbid cardiovascular disorders, pulmonary involvement, oncologic conditions, and osteoporosis. All these factors confound disease progression and treatment strategies, necessitating careful consideration of polypharmacy and modified drug metabolism. While the treatment principles largely align with those of Younge-Onset Rheumatoid Arthiritis (YORA), LORA management requires individualized approaches. Available evidence suggests that with proper monitoring, disease-modifying anti-rheumatic drugs (DMARDs) are safe and effective for older adults. Glucocorticoids should be minimized due to potential detrimental effects. Despite elevated baseline disease activity and functional deterioration, effectively managed LORA patients may achieve disease control similar to that of younger individuals. This review advocates for age-adjusted diagnostic strategies and patient-centered care models tailored to the needs of older RA patients. Addressing these unmet needs may enhance outcomes and quality of life for the growing population of LORA patients.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 6","pages":"152"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149268/pdf/","citationCount":"0","resultStr":"{\"title\":\"Late-onset rheumatoid arthritis: clinical features, diagnostic challenges, and treatment approaches.\",\"authors\":\"Olena Zimba, Chokan Baimukhamedov, Burhan Fatih Kocyigit\",\"doi\":\"10.1007/s00296-025-05908-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Late-Onset Rheumatoid Arthritis (LORA) is receiving increased clinical attention due to global aging trends. LORA presents distinct diagnostic, clinical, and therapeutic challenges. It often presents with a balanced gender distribution, acute onset, preferential involvement of larger joints, and decreased seropositivity. The diagnostic process is complex due to atypical presentations, comorbidities, and limitations of classification criteria, which insufficiently address the heterogeneity of LORA phenotypes. Patients with LORA often experience age-related geriatric syndromes, including frailty, cognitive decline, and malnutrition, in addition to comorbid cardiovascular disorders, pulmonary involvement, oncologic conditions, and osteoporosis. All these factors confound disease progression and treatment strategies, necessitating careful consideration of polypharmacy and modified drug metabolism. While the treatment principles largely align with those of Younge-Onset Rheumatoid Arthiritis (YORA), LORA management requires individualized approaches. Available evidence suggests that with proper monitoring, disease-modifying anti-rheumatic drugs (DMARDs) are safe and effective for older adults. Glucocorticoids should be minimized due to potential detrimental effects. Despite elevated baseline disease activity and functional deterioration, effectively managed LORA patients may achieve disease control similar to that of younger individuals. This review advocates for age-adjusted diagnostic strategies and patient-centered care models tailored to the needs of older RA patients. Addressing these unmet needs may enhance outcomes and quality of life for the growing population of LORA patients.</p>\",\"PeriodicalId\":21322,\"journal\":{\"name\":\"Rheumatology International\",\"volume\":\"45 6\",\"pages\":\"152\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149268/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00296-025-05908-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-025-05908-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Late-onset rheumatoid arthritis: clinical features, diagnostic challenges, and treatment approaches.
Late-Onset Rheumatoid Arthritis (LORA) is receiving increased clinical attention due to global aging trends. LORA presents distinct diagnostic, clinical, and therapeutic challenges. It often presents with a balanced gender distribution, acute onset, preferential involvement of larger joints, and decreased seropositivity. The diagnostic process is complex due to atypical presentations, comorbidities, and limitations of classification criteria, which insufficiently address the heterogeneity of LORA phenotypes. Patients with LORA often experience age-related geriatric syndromes, including frailty, cognitive decline, and malnutrition, in addition to comorbid cardiovascular disorders, pulmonary involvement, oncologic conditions, and osteoporosis. All these factors confound disease progression and treatment strategies, necessitating careful consideration of polypharmacy and modified drug metabolism. While the treatment principles largely align with those of Younge-Onset Rheumatoid Arthiritis (YORA), LORA management requires individualized approaches. Available evidence suggests that with proper monitoring, disease-modifying anti-rheumatic drugs (DMARDs) are safe and effective for older adults. Glucocorticoids should be minimized due to potential detrimental effects. Despite elevated baseline disease activity and functional deterioration, effectively managed LORA patients may achieve disease control similar to that of younger individuals. This review advocates for age-adjusted diagnostic strategies and patient-centered care models tailored to the needs of older RA patients. Addressing these unmet needs may enhance outcomes and quality of life for the growing population of LORA patients.
期刊介绍:
RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology.
RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.